Armata Pharmaceuticals, Inc. (ARMP)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.63 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$173.80M

Free cash flow

$26.31M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
31 Mar 2022	Innoviva, Inc. Director	Bought	$26.93M	49.0%
9 Feb 2022	Innoviva, Inc. Director	Bought	$18.07M	49.1%
29 Oct 2021	Innoviva, Inc. Director	Bought	$4.00M	19.7%
17 Mar 2021	Innoviva, Inc. Director	Bought	$13.93M	229%
26 Jan 2021	Innoviva, Inc. Director	Bought	$6.07M	opened
27 Mar 2020	Innoviva, Inc. 10% owner	Bought	$22.15M	777%

20out of 100

Profitability 0

Financial strength 20

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan